interleukin-17A

Treatment-Resistant Psoriatic Arthritis Improved by Ixekizumab

Treatment-Resistant Psoriatic Arthritis Improved by Ixekizumab

Ixekizumab benefits patients with treatment-resistant psoriatic arthritis when administered over a 2- or 4-week period.

Sign Up for Free e-Newsletters